Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval

[cafead]

via Biohaven’s attempts to redefine itself as a post-migraine company are continuing to encounter headaches, with the company expressing “deep disappointment” at the FDA’s refusal to review the brain disorder drug troriluzole.

article source